The ability of vitamin A to influence development is made possible by enzymes controlling the conversion of the alcohol form of vitamin A (retinol) first to an aldehyde (retinaldehyde) and then to a carboxylic acid (retinoic acid; RA) (). The first step of RA synthesis, oxidation of retinol to retinaldehyde, is catalyzed by several alcohol dehydrogenases (ADHs) and retinol dehydrogenases (RDHs). Genetic studies suggest that at least three ADHs (ADH1, ADH3, and ADH4) and two RDHs (RDH1 and RDH10) play a physiological role in RA synthesis (). Expression of these retinol-oxidizing enzymes is widespread and overlapping (
Ang et al., 1996;
Zhang et al., 2001;
Sandell et al., 2007). The second step of RA synthesis, oxidation of retinaldehyde to RA, is catalyzed by three retinaldehyde dehydrogenases (RALDH1, RALDH2, and RALDH3), which display non-overlapping tissue-specific patterns of expression during embryogenesis (
Mic et al., 2002) (). Oxidation of RA, which leads to its degradation, is carried out by three cytochrome P450 (CYP) enzymes known as CYP26A1 (
Abu-Abed et al., 2001), CYP26B1 (
Yashiro et al., 2004), and CYP26C1 (
Uehara et al., 2007). These enzymes also display unique tissue-specific patterns of expression during mouse embryogenesis, suggesting that they influence where RA signaling is able to occur in the embryo.
| Table 1Enzymes involved in RA synthesis during early organogenesis in mouse. |
RA serves as a ligand for two families of nuclear receptors that bind DNA and directly regulate transcription: (1) the RA receptors (RARα, RARβ, and RARγ) which bind the abundant form of RA known as all-
trans-RA, and (2) the retinoid X receptors (RXRα, RXRβ, and RXRγ) which bind an isomer known as 9-
cis-RA (
Chawla et al., 2001). However, 9-
cis-RA is normally undetectable except when vitamin A is present in excess (
Arnhold et al., 1996;
Mic et al., 2003). Hence, it may play a pharmacological but not a physiological role as an RXR ligand. As RXR forms heterodimers with RAR and several other nuclear receptors when bound to DNA, this suggests that RXR functions as a scaffold protein to facilitate DNA-binding for several different types of nuclear receptors (
Chawla et al., 2001). In vivo studies have demonstrated that ligand binding to just the RAR portion of RAR/RXR heterodimers is sufficient and necessary to rescue a lethal defect in RA synthesis, whereas ligand binding to RXR does not rescue the defect and is unnecessary (
Mic et al., 2003). When RA binds to the RAR partner of RAR/RXR heterodimers bound to a regulatory DNA element, this stimulates a cascade of events resulting in recruitment of transcriptional coactivators and initiation of transcription (
Germain et al., 2002).
RA is not produced by all cells of the body at all stages of development, but is instead produced in a unique spatiotemporal pattern. Retinol is secreted by the liver and transported in the blood at micromolar levels via serum retinol-binding protein (RPB4) and is made available to all cells (including embryonic cells by maternal transfer) for potential conversion to RA (
Quadro et al., 1999). Many cells possess STRA6, which functions as a membrane receptor for RBP4 to facilitate retinol uptake (
Kawaguchi et al., 2007). Many cells also contain cellular retinol-binding proteins (CRBPs) that bind retinol inside the cell (
Noy, 2000). CRBP1 has been proposed to facilitate conversion of retinol to retinyl esters for storage and to facilitate oxidation of retinol to retinaldehyde by RDHs, but not ADHs, for RA synthesis. These findings suggested that RDHs but not ADHs are important in endogenous RA synthesis. However, recent comparisons of ADH and RDH retinol enzymatic activity in the presence or absence of CRBP1 concluded that free retinol but not CRBP1-bound retinol is the substrate for both enzyme families (
Gallego et al., 2006). Also, mice lacking CRBP1 do not exhibit decreased RA synthesis but do have greatly reduced stores of liver retinyl esters, and are thus very sensitive to vitamin A deficiency (
Ghyselinck et al., 1999). Interestingly, mice lacking ADH1 have higher than normal levels of liver retinyl esters, and mice deficient in both ADH1 and CRBP1 have relatively normal levels of liver retinyl esters and reduced sensitivity to vitamin A deficiency (
Molotkov et al., 2004). Thus, ADH1 and CRBP1 have opposing roles in the liver that prevent toxic accumulation of retinol but still enable a large fraction of retinol to become esterifed as a stored form, thus providing a continuous source of retinol to be secreted into the blood for use in peripheral tissues including embryos.
Studies on mice carrying null mutations in ADH and RDH enzymes suggest that oxidation of retinol to retinaldehyde may be controlled in vivo by multiple genes (). Mice lacking ADH1 are susceptible to retinol toxicity, yet are otherwise phenotypically normal, indicating that oxidation of retinol by ADH1 contributes to removal of excess retinol (via further metabolism to RA and oxidized forms of RA) rather than contributing to RA needed for signaling (
Molotkov et al., 2002a). In contrast, loss of ADH3 and ADH4 impairs postnatal survival during vitamin A deficiency suggesting potential roles in RA synthesis designed for RA signaling (
Molotkov et al., 2002b). However, given that ADH3 has very low activity for retinol oxidation (
Molotkov et al., 2002b), the effect of its knockout may be unrelated to RA synthesis. In comparison, ADH4 and RDH1 are very efficient in retinol oxidation (
Zhang et al., 2001;
Gallego et al., 2006), yet mice lacking ADH4 and RDH1 have not been shown to display detectable alterations in embryonic RA signaling (
Molotkov et al., 2002b;
Zhang et al., 2007). Among these genes, only mutants in
Rdh10 have a serious defect in embryonic RA signaling resulting in embryonic lethality at embryonic day 13 (E13) (
Sandell et al., 2007).
Rdh10 mutant embryos still maintain RA signaling in some embryonic tissues, suggesting that ADH1, ADH3, ADH4, or RDH1, which are all expressed in embryos, may also function to generate retinaldehyde for RA synthesis.
Retinol oxidation is a reversible reaction. Hence, the ability to convert retinaldehyde back to retinol, a reaction that multiple enzymes can accomplish, may provide further control over RA synthesis (
Gallego et al., 2006). In contrast, oxidation of retinaldehyde to RA is irreversible. Given the widespread access to retinol via the circulatory system, it is possible that all cells establish an equilibrium between retinol and retinaldehyde, but only cells expressing one of the RALDHs can oxidize the available retinaldehyde to RA.
Conversion of retinol to RA occurs at relatively low levels, but RA has been detected in mouse embryos using sensitive RA-reporter assays. Evidence from a mouse strain that bears a transgene expressing
lacZ under the control of a retinoic acid response element (RARE) indicates that RA signaling activity is first observed at E7.5, the late primitive streak stage, and is localized to the trunk from E7.5–E8.5 (
Rossant et al., 1991). An RA-reporter cell line was used to demonstrate that mouse embryo explants from E7.5, but not E6.5, have detectable RA activity (
Ang et al., 1996). The RA biosynthetic enzyme RALDH2 is first expressed at E7.5 in trunk paraxial mesoderm and by E8.5 displays expression in paraxial and lateral plate mesoderm that appears quite similar to the pattern of RA localization (
Sirbu et al., 2005;
Molotkova et al., 2005). Studies on mice lacking RALDH2 have shown that it is responsible for all RA signaling activity in the embryo from E7.5 (
Sirbu et al., 2005) to E8.5 (
Molotkova et al., 2005), but that immediately after this stage RALDH1 and RALDH3 also contribute to RA synthesis in the eye and olfactory pit (
Molotkov et al., 2006).
RA released by RA-generating cells can enter adjacent cells where it has two main fates (). In cells expressing one of the
Cyp26 genes, RA is degraded and RA signaling is prevented (
Hernandez et al., 2007;
Uehara et al., 2007) . In cells not expressing
Cyp26, RA can enter the nucleus and bind to RAR receptors leading to transcription of target genes. Additionally, some cells express cellular RA-binding protein-2 (CRABP2), which greatly facilitates cellular uptake of RA and transfer to the nucleus (
Sessler and Noy, 2005;
Schug et al., 2007).